Lin, Chujiao
Yang, Qiyuan
Guo, Dongsheng
Xie, Jun http://orcid.org/0000-0001-9565-1567
Yang, Yeon-Suk
Chaugule, Sachin http://orcid.org/0000-0001-6323-2034
DeSouza, Ngoc
Oh, Won-Taek http://orcid.org/0000-0003-1815-0851
Li, Rui http://orcid.org/0000-0003-3193-1396
Chen, Zhihao
John, Aijaz A.
Qiu, Qiang
Zhu, Lihua Julie http://orcid.org/0000-0001-7416-0590
Greenblatt, Matthew B. http://orcid.org/0000-0001-9794-8532
Ghosh, Sankar http://orcid.org/0000-0002-3227-0588
Li, Shaoguang http://orcid.org/0000-0002-8947-9614
Gao, Guangping http://orcid.org/0000-0003-0097-9012
Haynes, Cole http://orcid.org/0000-0003-2110-5648
Emerson, Charles P.
Shim, Jae-Hyuck http://orcid.org/0000-0002-4947-3293
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR075585)
Pershing Square Foundation
Article History
Received: 17 January 2022
Accepted: 27 October 2022
First Online: 11 November 2022
Competing interests
: G.G. and J.H.S. are co-founders of AAVAA Therapeutics and hold equity of this company. G.G. is a scientific co-founder of Voyager Therapeutics and Aspa Therapeutics Inc., and an inventor on patents with potential royalties licensed to other biopharmaceutical companies, in which they hold equity. Other authors declare no competing interests.